register

Medical and Science

Government urged to tackle 14-year decline in R&D investment

Health Industry Hub | May 16, 2024 |

Medical: There is an urgency to counter the fourteen-year downward trend in research and development (R&D) investment, positioning Australia unfavourably below the OECD average and hindering its competitiveness on the global stage.

In the Federal Budget, the government announced a strategic examination of the nation’s R&D system, which has been welcomed by the Australian Academy of Science.

Academy President, Professor Chennupati Jagadish, said “The Academy has been arguing the case for this long-overdue whole-of-sector analysis since 2018. It is a necessary precursor to the creation of a strategic roadmap that can direct R&D in Australia and reverse the 14-year decline in investment that has left Australia uncompetitive and ill-equipped to meet our national ambitions.”

Presently, Australia’s investment in science and research spans across 227 programs and 15 federal portfolios, with diverse ministerial and departmental responsibilities.

Professor Jagadish stressed “A strategic examination of Australia’s R&D system is the first step to align national effort across the whole of government, industry, universities and philanthropy to create an environment where investment is effective, strategic and scaled.

“The examination is cross-portfolio and cross-sectoral and is a once-in-a-generation opportunity to create the necessary conditions for science and research to maximise its contribution to our national prosperity.”

Earlier this month, the Academy announced its development of a 10-year plan aimed at ensuring Australia’s scientific readiness to navigate an unpredictable future and advance local and global interests.

Professor Jagadish affirmed that the Academy’s forthcoming 10-year plan, slated for publication later this year, will complement the strategic evaluation outlined in the Budget, offering an additional and independent perspective on Australia’s scientific trajectory.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

APAC medtech company scores TGA approval in heart disease

APAC medtech company scores TGA approval in heart disease

Health Industry Hub | October 4, 2024 |

MedTech & Diagnostics News: An Asia Pacific medtech company has announced that its flagship drug-eluting stent (DES) has received regulatory […]

More


News & Trends - MedTech & Diagnostics

New state-based pilot to back home-grown medtech innovation

New state-based pilot to back home-grown medtech innovation

Health Industry Hub | October 4, 2024 |

MedTech & Diagnostics: In a bid to enhance opportunities for local medtech manufacturers to sell to health services, a connected […]

More


News & Trends - Pharmaceuticals

Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis

Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis

Health Industry Hub | October 4, 2024 |

Pharma News: Ferring Pharmaceuticals has announced results from a new study, which provides the first real-world evidence supporting the efficacy […]

More


News & Trends - Pharmaceuticals

Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives

Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives

Health Industry Hub | October 4, 2024 |

Pharma News: Australian women are calling for more accurate information about their contraceptive options, with 70% feeling inadequately educated about […]

More


This content is copyright protected. Please subscribe to gain access.